Last reviewed · How we verify
Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy
Approved treatments
- Azd5363 · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy patent landscape — cliff calendar, originator estates, attackable patents
- Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy treatment landscape brief
- Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy treatment updates RSS
Frequently asked questions about Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy
What drugs treat Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy?
Tracked treatments include Azd5363.
What is the treatment for Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy?
Standard treatment for Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy includes Azd5363. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy patent cliff · Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy CI report
- Treatment: Azd5363 · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing